Abstract

BackgroundIt is a known fact that arginine is a common substrate for arginase and nitric oxide synthase (NOS). However, an imbalance between both enzymes could lead to a change in airway responses. Reports suggest that increased activities of both enzymes could lead to airway hyper-responsiveness. Thus, the requests for NOS inhibitors that can also inhibit arginase as the elevated activities of both enzymes have detrimental consequence on airways in asthma. Bioactive compounds from Azadirachta indica, Crinum glaucum, and Mangifera indica are documented for anti-inflammatory, immunomodulatory, anti-histaminic, smooth-muscle relaxants, and anti-allergic potentials. However, the mechanisms of action of these bioactive compounds in conferring the aforementioned protections are not well characterized. The objective of this present study is to assess in silico inhibitory potentials of these bioactive compounds against NOS and arginase via binding at their active sites. The crystal structures of NOS and arginase were retrieved from the protein database, while the bioactive compounds were retrieved from PubChem. Drug-likeness of the selected bioactive compounds was assessed using DruLiTo software. The successful compounds were docked with active sites of enzymes using AutoDock Vina docking software, and the docked complexes were analyzed using LigPlot and protein-ligand profiler web server.ResultsThe findings of the study revealed that the bioactive compounds from A. indica, C. glaucum, and M. indica were able to interact with the active sites of NOS and arginase with the exception of gallic acid (from M. indica) and nimbandiol (from A. indica); these compounds showed differential binding energies (kcal/mol) and a number of them had higher binding energies than l-arginine when docked with NOS.ConclusionConclusively, the in silico analysis proposes that these compounds could prove to be probable anti-asthmatic drugs.

Highlights

  • It is a known fact that arginine is a common substrate for arginase and nitric oxide synthase (NOS)

  • The three-dimensional (3D) crystallographic structures of human endothelial NOS complexed with arginine (PDB code: 3NOS) and human arginase I in complex with known inhibitor methionine 2(S)-amino-6-boronohexanoic acid (Me-ABH) with PDB code: 3SJT were retrieved from the Protein Database (PDB)

  • Arginase I is homodimerically crystalized with Me-ABH, which is having a protein length of 322 amino acids and resolution of 1.60 Å (Fig. 2)

Read more

Summary

Introduction

It is a known fact that arginine is a common substrate for arginase and nitric oxide synthase (NOS). The mechanisms of action of these bioactive compounds in conferring the aforementioned protections are not well characterized The objective of this present study is to assess in silico inhibitory potentials of these bioactive compounds against NOS and arginase via binding at their active sites. While eNOS and nNOS are constitutively expressed depending on the increases in external calcium and the binding of a calcium/calmodulin complex for activation. Both nNOS and eNOS play a pertinent role in neurotransmission and smooth muscle relaxation, while iNOS is usually expressed during bacterial infection, inflammation, and tumor cell lysis [2, 3]. Arginase is not limited to hepatocytes and other cells in the lung and airways [4, 5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call